Gracevit (sitafloxacin) / Daiichi Sankyo - LARVOL DELTA

SUCCESSFUL TREATMENT WITH CLOFAZIMINE FOR MACROLIDE-RESISTANT MYCOBACTERIUM ABSCESSUS INFECTION IN A PERITONEAL DIALYSIS PATIENT (ISN-WCN 2026) - "The patient transitioned to hemodialysis following catheter removal 11 days after symptom onset, with extensive surgical debridement and a 6-week combination antibiotic therapy including imipenem-cilastatin, amikacin and clarithromycin, achieving clinical cure. However, the infection recurred after 5 months, necessitating retreatment with debridement and an antibiotic regimen including imipenem-cilastatin, amikacin, azithromycin and clofazimine for 4 weeks, followed by a continuation regimen with amikacin, clofazimine and sitafloxacin for 4 months...Our case represents the first successful treatment of macrolide-resistant M. abscessus PD-associated infection using clofazimine-containing combination therapy, demonstrating clofazimine as a potential therapeutic option in combination therapy. Multimodal therapy including early catheter removal, extensive surgical debridement, and prolonged multidrug antimicrobial regimens containing clofazimine may represent a viable..."

Clinical • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Infectious Disease • Nephrology • Nontuberculous Mycobacterial Disease • Polycystic Kidney Disease • Renal Disease • Respiratory Diseases • Tuberculosis • CRP

SUCCESSFUL SALVAGE OF A PERITONEAL DIALYSIS CATHETER IN A CASE OF NONTUBERCULOUS MYCOBACTERIAL INFECTION (ISN-WCN 2026) - "Despite topical gentamicin, the discharge worsened. On Day -8, ultrasound showed a peri-catheter hypoechoic area consistent with TI, a swab for culture was obtained, and oral cefaclor was started...Empiric therapy with linezolid, amikacin, and clarithromycin was started on Day 1...Current guidance highlights NTM among atypical causes of refractory ESI, encourages individualized salvage strategies including exit-site relocationConclusion In PD patients with refractory ESI/TI, clinicians should obtain early AFB cultures and species identification to guide management. Early exit-site revision/debridement with an oral dual regimen of clarithromycin and sitafloxacin can salvage the catheter and maintain PD when cardiac dysfunction and obesity limit alternatives, demonstrating a practicalt success where evidence remains limited."

Clinical • Nontuberculous mycobacteria • Cardiovascular • Genetic Disorders • Heart Failure • Hematological Disorders • Infectious Disease • Nontuberculous Mycobacterial Disease • Obesity • Respiratory Diseases • Thrombocytopenia

Successful treatment with clofazimine for macrolide-resistant Mycobacterium abscessus infection in a peritoneal dialysis patient: A case report and literature review. (PubMed, Perit Dial Int) - "Initial management included early catheter removal, extensive surgical debridement, and 6 weeks of combination antibiotic therapy, including imipenem-cilastatin, amikacin, and clarithromycin, achieving clinical cure. However, the infection recurred after 5 months, necessitating retreatment with debridement and an antibiotic regimen including imipenem-cilastatin, amikacin, azithromycin, and clofazimine for 4 weeks, followed by a continuation regimen with amikacin, clofazimine, and sitafloxacin for 4 months...Based on a literature review of 67 cases of M. abscessus PD-associated infections, all six cases treated with clofazimine achieved clinical cure, but there were no reports on cases of macrolide-resistant M. abscessus treated with clofazimine. Our case represents the first successful clofazimine treatment of macrolide-resistant M. abscessus PD-associated infection, demonstrating clofazimine as a potentially effective oral antibiotic option in combination therapy,..."

Journal • Infectious Disease • Inflammation • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Effects of hydroxybisphosphonates-conjugated sitafloxacin on fracture healing and skeletal growth in mice. (PubMed, JBMR Plus) - "To address this, we assessed HBCS effects vs placebo, zoledronic acid (ZA) positive control known to inhibit osteoclasts and increase fracture callus and growth plate bone volume, and hydroxy-phenyl-ethane-hydroxy-bisphosphonate (HPHBP), the bisphosphonate component of HBCS, using a murine closed femur fracture model, and on intramembranous and endochondral ossification in the proximal tibia of 12-wk-old mice. However, HPHBP and HBCS increased growth plate bone volume over total volume (BV/TV) concomitant with a decrease in osteoclasts, while ZA further increased total bone volume and BV/TV with a dramatic increase in osteoclasts. Collectively, these data demonstrate that while HBCS decreases osteoclast numbers in vivo, it does not inhibit fracture healing or normal bone growth in mice."

Journal • Preclinical • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics

Superbugs Neisseria gonorrhoeae und Mycoplasma genitalium : Therapeutic challenges driven by antimicrobial resistance (PubMed, Dermatologie (Heidelb)) - "N. gonorrhoeae is showing increasing resistance to penicillins, tetracyclines, and fluoroquinolones; furthermore, there is a growing reduction in susceptibility to the macrolide antibiotic azithromycin. Resistance rates to ceftriaxone, the current first-line therapy in many international treatment guidelines, and to cefixime, the peroral treatment option frequently used in outpatient settings, remain very low in German-speaking countries. For M. genitalium, increasing resistance is observed primarily to macrolides and, less commonly, to fluocinolones; cases of infections with combined resistance to both antimicrobial classes have been reported and regularly require the use of reserve antibiotics such as pristinamycin or sitafloxacin. Enhanced surveillance, molecular resistance testing, avoidance of overdiagnosis, rational and responsible antibiotic use (preventing overtreatment), and the development and implementation of new antimicrobial agents are..."

Journal • Review • Infectious Disease

A single-center culture-based study of Helicobacter pylori in Kazakhstan with regional meta-analysis of prevalence and antibiotic resistance. (PubMed, Front Microbiol) - "Resistance rates among 86 isolates were 87.2% to metronidazole, 33.7% to clarithromycin, and 3.5% to amoxicillin; no resistance was detected to minocycline or sitafloxacin. Absence of resistance to minocycline and sitafloxacin supports their use in rescue regimens. These findings highlight the urgent need for national surveillance, updated treatment guidelines, and integration of molecular resistance monitoring to improve evidence-based management of H. pylori in Central Asia."

Journal • Retrospective data • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

Third-Line and Later Susceptibility-Guided Helicobacter pylori Eradication Therapies: A Multicenter Study of Vonoprazan-Amoxicillin-Sitafloxacin/Rifabutin Regimens. (PubMed, J Clin Med) - " Susceptibility-guided vonoprazan-based regimens from the third-line treatment onward achieved high eradication and tolerability in a multicenter cohort. This approach may offer a valuable treatment option for patients with refractory H. pylori infections."

Clinical • Journal • Infectious Disease

Clinical epidemiology and management challenges of genital Mycoplasma and Ureaplasma infections: A retrospective observational study at a Japanese urban clinic. (PubMed, Sex Health) - "In a Tokyo clinical setting, M. genitalium was the most prevalent species and the primary driver of symptoms, whereas M. hominis and Ureaplasma spp. frequently suggest colonization. Management remains challenging due to suboptimal cure rates and poor follow-up adherence. These findings support a tiered diagnostic strategy that prioritizes exclusion of major sexually transmitted infections and emphasizes species-specific management."

Journal • Observational data • Retrospective data • Infectious Disease

A PAN-USR TB Multi-Center Trial (clinicaltrials.gov) - P3 | N=610 | Recruiting | Sponsor: Shenzhen Third People's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Challenges and Efficacy of Amikacin Liposome Inhalation in Real-World Refractory Mycobacterium avium Complex Pulmonary Disease. (PubMed, Cureus) - "Prior treatment regimens primarily involved azithromycin- or clarithromycin-based therapies, supplemented with sitafloxacin, with a median treatment duration of five years. These findings highlight the challenges of managing refractory MAC pulmonary disease in a real-world setting and emphasize the importance of considering patient characteristics, including radiographic patterns and baseline health, when initiating ALIS therapy. Adverse events were frequent but manageable with appropriate monitoring and adjustments."

Journal • Real-world evidence • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases

Challenges and Efficacy of Amikacin Liposome Inhalation in Real-World Refractory Mycobacterium Avium complex Pulmonary Disease (APSR 2025) - "Prior to ALIS initiation, patients had received macrolide-based regimens (azithromycin or clarithromycin) with sitafloxacin for a median duration of five years. While generally tolerable, the adverse event profile warrants careful monitoring. These findings highlight the importance of patient selection and potentially earlier ALIS intervention, particularly in patients with NB pattern disease."

Clinical • Real-world • Real-world evidence • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases

Clinical efficacy of sitafloxacin-containing regimens for Mycobacterium avium complex pulmonary disease. (PubMed, BMC Pulm Med) - No abstract available

Journal • Pulmonary Disease • Respiratory Diseases

In Vitro Activity of Sulfamethoxazole-Trimethoprim, Amikacin, Oxazolidinones, Fluoroquinolones and Fidaxomicin against Isolates of Nocardia. (PubMed, ACS Omega) - "This study evaluates the in vitro activity of common and potential antimicrobials, including Trimethoprim-sulfamethoxazole, Amikacin, Oxazolidinones (Linezolid, Tedizolid, Contezolid), Fluoroquinolones (Moxifloxacin, Levofloxacin, Sitafloxacin), Rifampicin, and Fidaxomicin against 51 clinical Nocardia isolates. These findings highlight the need for tailored treatment strategies based on species-specific susceptibility and resistance profiles and suggest Fidaxomicin and Sitafloxacin as promising options. Further clinical validation is warranted to optimize therapeutic outcomes."

Journal • Preclinical • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Efficacy of a 7-day vonoprazan, sitafloxacin, and amoxicillin triple therapy as a fourth-line salvage regimen for refractory Helicobacter pylori infection. (PubMed, BMC Gastroenterol) - No abstract available

Journal • Infectious Disease

In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin. (PubMed, J Antimicrob Chemother) - "Mutations in multiple genes conferring fluoroquinolone resistance appeared with regularity in vitro. Findings of an additive effect for ParC/GyrA changes, and greater effectiveness of sitafloxacin against resistant bacteria compared with moxifloxacin, are both consistent with clinical data. Improved understanding of fluoroquinolone resistance will inform the development of diagnostic assays predicting fluoroquinolone susceptibility."

Journal • Preclinical

Characteristics of Successful Third-Line Eradication of Helicobacter pylori based on Antibiotic Susceptibility. (PubMed, Asian Pac J Cancer Prev) - "VPZ, AMX, and STFX regimens were the most common and effective regimens, with female and AMX-sensitive patients more likely to have successful third-line eradication."

Journal • Infectious Disease

Improving Levothyroxine Adherence in an Elderly Polypharmacy Patient: A Multifaceted Intervention (ATA 2025) - "Introduction : Methimazole achieves high three-month compliance rates (~83%), thanks to once-daily dosing and low burden 1)...Current medications included levothyroxine, sitafloxacin, clofazimine, and entecavir, with a history of numerous antibiotics...Additionally, pharmacist-supported TSH monitoring programs reduced non-compliance from 79 to 18%, with 60% of patients actively managing dosing 5). This case emphasizes that to improve levothyroxine adherence in complex elderly patients, a multifaceted approach is essential—from using patient-friendly formulations and digital reminders to integrating pharmacist-led TSH monitoring."

Adherence • Clinical • Late-breaking abstract • Alzheimer's Disease • Atrial Fibrillation • Cardiovascular • Cognitive Disorders • Fatigue • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis

In vitro activity of sulbactam in combination with other antimicrobial agents against extensively drug-resistant Acinetobacter baumannii. (PubMed, Microbiol Spectr) - "Sixty-two clinical isolates of XDR A. baumannii were tested for minimal inhibitory concentrations (MICs) of SUL, amikacin (AMI), ciprofloxacin, colistin (COL), fosfomycin (FOS), gentamicin, meropenem (MER), rifampicin (RIF), sitafloxacin (SIT), and tigecycline (TIG) using broth microdilution. Time-kill assays showed that the four-drug combination of SUL/fosfomycin/amikacin/meropenem had sustained bactericidal activity over 24 hours. While SUL-based combinations showed variable synergy, further studies are needed to determine their clinical potential."

Journal • Preclinical • Infectious Disease

Endoscopically confirmed treatment progression in Mycoplasma genitalium-induced proctitis:a case report (PubMed, Nihon Shokakibyo Gakkai Zasshi) - "Sitafloxacin (200mg/day) was administered for 2 weeks, after which the bloody stools and fever resolved...To date, no reports have described endoscopic images of M. genitalium-induced proctitis. This was a valuable case in which we followed the treatment progression of M. genitalium-induced proctitis endoscopically."

Journal • Colorectal Cancer • Cytomegalovirus Infection • Infectious Disease • Nephrology

Elderly-USR: Ultra-Short Regimen for Elderly DS-TB (clinicaltrials.gov) - P3 | N=300 | Not yet recruiting | Sponsor: Shenzhen Third People's Hospital

New P3 trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

A Pan-Ultrashort Regimen for Drug-susceptible and Drug-resistant Pulmonary Tuberculosis: A Multi-Center Randomized Controlled Trial (ChiCTR) - P=N/A | N=610 | Not yet recruiting | Sponsor: Shenzhen Third people's Hospital; Shenzhen Third people's Hospital | Phase classification: P4 ➔ P=N/A

Phase classification • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones. (PubMed, J Antimicrob Chemother) - "Nocardia spp. exhibited varying patterns of susceptibility to carbapenems and fluoroquinolones respectively. Importantly, different Nocardia spp. exhibited different patterns of susceptibility to carbapenems and fluoroquinolones, respectively."

Journal

Susceptibility of Neisseria gonorrhoeae to Zoliflodacin and Quinolones in Hyogo Prefecture, Japan. (PubMed, Pathogens) - "In addition to ZFD, we investigated the susceptibility of N. gonorrhoeae strains to ceftriaxone (CTRX), ciprofloxacin (CPFX), garenoxacin (GRNX), and sitafloxacin (STFX). ZFD showed potent antimicrobial activity against N. gonorrhoeae strains that are highly resistant to quinolones. It may become a new option in the treatment of gonococcal infections."

Journal • Infectious Disease

Disseminated Mycobacterium abscessus Infection in a Three-Year-Old Girl With CHARGE Syndrome: A Case Report and Literature Review. (PubMed, Cureus) - "Following microbiologic diagnosis, treatment was started with azithromycin and imipenem/cilastatin, along with exchanges of the intravenous device. However, subsequent deterioration of her condition required the admission to the intensive care unit and finally led to the introduction of a four-agent regimen with azithromycin, amikacin, linezolid, and tigecycline, whose sensitivity was confirmed later. After the initiation of sensitive antimicrobial therapy, she gradually recovered and was discharged with oral azithromycin and sitafloxacin...Although her immune function showed no abnormalities, we identified several predisposing factors related to her post-septic condition and her congenital medical history through an investigation of her clinical features with a literature review. While some previous cases of disseminated rapid-growing mycobacterial infections were successfully managed by intravascular device removal alone, this case underscores the need for tailored..."

Journal • Critical care • Infectious Disease • Nontuberculous Mycobacterial Disease • Otorhinolaryngology • Pediatrics • Respiratory Diseases

Infection in glaucoma drainage implant caused by macrolide-resistant Mycobacterium abscessus subsp. abscessus. (PubMed, Diagn Microbiol Infect Dis) - "Infection recurred, requiring surgical debridement and prolonged therapy with amikacin, clofazimine, and sitafloxacin based on susceptibility results. The organism's ability to form biofilms and resist multiple antimicrobials-especially through inducible macrolide resistance-complicates treatment. Early removal of infected devices and susceptibility-guided antimicrobial selection are essential for infection control."

Journal • Glaucoma • Infectious Disease • Ophthalmology